Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc.verified

NBIX

Price:

$120.17

Market Cap:

$12.13B

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a...[Read more]

Industry

Drug Manufacturers - Specialty & Generic

IPO Date

1996-05-23

Stock Exchange

NASDAQ

Ticker

NBIX

The Enterprise Value as of September 2024 (TTM) for Neurocrine Biosciences, Inc. (NBIX) is 12.29B

According to Neurocrine Biosciences, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 12.29B. This represents a change of -6.66% compared to the average of 13.16B of the last 4 quarters.

Neurocrine Biosciences, Inc. (NBIX) Historical Enterprise Value (quarterly & annually)

How has NBIX Enterprise Value performed in the past?

The mean historical Enterprise Value of Neurocrine Biosciences, Inc. over the last ten years is 7.50B. The current 12.29B Enterprise Value has changed 16.28% with respect to the historical average. Over the past ten years (40 quarters), NBIX's Enterprise Value was at its highest in in the June 2024 quarter at 14.27B. The Enterprise Value was at its lowest in in the September 2014 quarter at 1.16B.

Quarterly (TTM)
Annual

Average

7.50B

Median

7.61B

Minimum

1.64B

Maximum

13.05B

Neurocrine Biosciences, Inc. (NBIX) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Neurocrine Biosciences, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 187.81%

Maximum Annual Enterprise Value = 13.05B

Minimum Annual Increase = -30.58%

Minimum Annual Enterprise Value = 1.64B

Quarterly (TTM)
Annual
YearEnterprise ValueChange
202313.05B14.05%
202211.44B40.28%
20218.16B-4.43%
20208.53B-16.59%
201910.23B44.95%
20187.06B1.69%
20176.94B112.52%
20163.27B-30.58%
20154.71B187.81%
20141.64B182.34%

Neurocrine Biosciences, Inc. (NBIX) Average Enterprise Value

How has NBIX Enterprise Value performed in the past?

The current Enterprise Value of Neurocrine Biosciences, Inc. (NBIX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

10.88B

5-year avg

10.28B

10-year avg

7.50B

Neurocrine Biosciences, Inc. (NBIX) Enterprise Value vs. Peers

How is NBIX’s Enterprise Value compared to its peers?

Neurocrine Biosciences, Inc.’s Enterprise Value is greater than Amphastar Pharmaceuticals, Inc. (2.64B), greater than Collegium Pharmaceutical, Inc. (1.58B), greater than Ironwood Pharmaceuticals, Inc. (1.26B), greater than ANI Pharmaceuticals, Inc. (1.34B), greater than Deciphera Pharmaceuticals, Inc. (2.15B), greater than Alkermes plc (4.26B), greater than Avadel Pharmaceuticals plc (1.40B), greater than Intra-Cellular Therapies, Inc. (7.09B), greater than Dynavax Technologies Corporation (1.59B), greater than Pacira BioSciences, Inc. (1.04B), greater than Eagle Pharmaceuticals, Inc. (110.03M), greater than Prestige Consumer Healthcare Inc. (4.75B), greater than Evotec SE (1.33B), greater than Supernus Pharmaceuticals, Inc. (1.85B),

Build a custom stock screener for Neurocrine Biosciences, Inc. (NBIX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Neurocrine Biosciences, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Neurocrine Biosciences, Inc. (NBIX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Neurocrine Biosciences, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is Neurocrine Biosciences, Inc.'s Enterprise Value?

What is the highest Enterprise Value for Neurocrine Biosciences, Inc. (NBIX)?

What is the 3-year average Enterprise Value for Neurocrine Biosciences, Inc. (NBIX)?

What is the 5-year average Enterprise Value for Neurocrine Biosciences, Inc. (NBIX)?

How does the current Enterprise Value for Neurocrine Biosciences, Inc. (NBIX) compare to its historical average?